Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Blood-stage Plasmodium parasites are the asexual developmental forms of Plasmodium that invade and replicate within human red blood cells. These stages (ring, trophozoite, and schizont) are responsible for the clinical manifestations of malaria, including fever, anemia, and, in severe cases, organ failure. The parasites digest host hemoglobin and undergo mitotic replication (schizogony), releasing merozoites that reinvade new red cells. All current frontline antimalarial drugs are designed to kill or inhibit these blood stages, which are essential for malaria pathogenesis and transmission. These stages are not a single molecular entity but represent a critical therapeutic target category in malaria control and eradication efforts.
Inhibition of heme detoxification (e.g., chloroquine); Generation of reactive oxygen species (e.g., artemisinins); Inhibition of mitochondrial electron transport (e.g., atovaquone); Inhibition of folate metabolism (e.g., pyrimethamine, sulfadoxine); Direct disruption of parasite protein synthesis or transport (e.g., doxycycline, tetracyclines)
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium blood-stage parasite.